HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a $16 price target.
August 11, 2023 | 4:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Panbela Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $16.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Panbela Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100